FDA Needs Cure for Conflict – HeraldNet

Read article - Lisa Schwartz, professor of medicine, community and family medicine, and of The Dartmouth Institute for Health Policy and Clinical Practice, is quoted about how the FDA has set a disturbing precedent by approving an untested dose of the new insomnia drug Belsomra. "For a deadly cancer with limited treatment this gamble might make sense, but not for a condition like insomnia and where Belsomra doesn't appear to work any better, or more safely, than available treatments," says Schwartz.